HotCopper on MSN

Last year's anti-sweat biotech darling Botanix falls -10% on poorly received quarterly

Botanix Pharma (ASX:BOT) saw its share price fall around -10% on Tuesday as the company’s latest quarterly update, in which ...
Hosted on MSN

Dr Boreham’s Crucible: Can Sofdra become the ‘world’s most successful dermatology drug?’

Botanix Pharmaceuticals (ASX:BOT) CEO Dr Howie McKibbon says investors shouldn’t rely just on management’s assertion that its anti-sweating drug Sofdra has – and we paraphrase – “the potential to be ...